Genomed Spólka Akcyjna (WSE:GEN)

Market Cap	33.83M
Revenue (ttm)	25.14M
Net Income (ttm)	2.20M
Shares Out	1.32M
EPS (ttm)	n/a
PE Ratio	15.38
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1
Average Volume	16
Open	25.60
Previous Close	n/a
Day's Range	25.60 - 25.60
52-Week Range	23.00 - 29.20
Beta	-0.10
RSI	53.24
Earnings Date	Aug 11, 2025

About Genomed Spólka Akcyjna

Genomed Spólka Akcyjna provides DNA sequencing and analysis, and diagnostics of congenital diseases in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company’s diagnostic services include DNA isolation, PCR amplification and Sanger sequencing of DNA regions, the comparison of the sequences, and the interpretation of the results by diagnosticians. In addition, it provides various types of DNA sequence analysis, including polymorphism a...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2007
• Employees: 54
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: GEN

Financial Performance

In 2024, Genomed Spólka Akcyjna's revenue was 23.01 million, an increase of 2.34% compared to the previous year's 22.48 million. Earnings were 1.11 million, an increase of 19.32%.